aflibercept-mrbb (Ahzantive) vs Brolucizumab-Dbll

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

aflibercept-mrbb (Ahzantive)

Marketed by Formycon AG and partners

Approved in Age-Related Macular Degenerationfusion protein
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Age-Related Macular Degenerationantibody fragment (scFv)
Weak signal

NCT05672979 · Phase 3 · status unknown

This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.

No aligned efficacy figure on record for this race.

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

aflibercept-mrbb (Ahzantive): registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.

Brolucizumab-Dbll: registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.

Wet Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Wet Age-Related Macular Degeneration pipeline

aflibercept-mrbb (Ahzantive)

Marketed by Formycon AG and partners

Approved in Wet Age-Related Macular Degenerationfusion protein
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Wet Age-Related Macular Degenerationantibody fragment (scFv)
Reliable signal

NCT02307682 · Phase 3 · completed

Randomized, double-blind, active-controlled Phase 3 trial in 1,078 treated patients with neovascular AMD; the primary endpoint was change in best-corrected visual acuity at 48 weeks. Both brolucizumab doses met the prespecified non-inferiority margin versus aflibercept (3 mg difference -0.6 letters, 95% CI -2.5 to 1.3; 6 mg difference -0.2 letters, 95% CI -2.1 to 1.8; margin 4 letters), providing strong comparative evidence that brolucizumab is not worse than aflibercept on this functional endpoint.

No aligned efficacy figure on record for this race.

Results for Wet Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

aflibercept-mrbb (Ahzantive): registry results are on file for Wet Age-Related Macular Degeneration, but their comparison mappings are not yet available.

Brolucizumab-Dbll: registry results are on file for Wet Age-Related Macular Degeneration, but their comparison mappings are not yet available.

Diabetic Macular Edema

Shared mechanism: VEGF-A · full Diabetic Macular Edema pipeline

aflibercept-mrbb (Ahzantive)

Marketed by Formycon AG and partners

Approved in Diabetic Macular Edemafusion protein
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Diabetic Macular Edemaantibody fragment (scFv)
Partial signal

NCT04955171 · Phase 3 · status unknown

Randomized, active-comparator trial testing brolucizumab head-to-head against an established anti-VEGF therapy for diabetic macular edema, though masking was limited to participants only and the trial is relatively small. Results are not yet available.

No aligned efficacy figure on record for this race.

Results for Diabetic Macular Edema

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

aflibercept-mrbb (Ahzantive): no structured comparison results are available for Diabetic Macular Edema.

Brolucizumab-Dbll: no structured comparison results are available for Diabetic Macular Edema.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aflibercept-mrbb (Ahzantive)'s landscape · Brolucizumab-Dbll's landscape